プレスリリース

トニー・オニール氏が、味の素バイオファーマ・サービスの経営陣にコンプライアンス担当副社長として加わった

January 25, 2022 – San Diego, CA – Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading global provider of bio-pharmaceutical contract development and manufacturing services, is pleased to announce that Tony O’Neill has joined Aji Bio-Pharma as Vice President of Compliance, US Operations. Mr. O’Neill brings extensive experience leading Quality, Manufacturing, and Operational Excellence Teams in the pharmaceutical and bio-pharmaceutical industry.

Mr. O’Neill joins Aji Bio-Pharma after 25 years at Allergan, where he held a number of Quality and Operational leadership positions in biologics manufacturing and development with responsibility both in Ireland and US operations. His most recent roles include Executive Director Quality Operations and Executive Director Risk Management and Compliance, where he was responsible for leading a team in developing standard policies and processes for data management and controls across a network of 14 sites.

“We are excited to welcome Tony O’Neill to our leadership team at Aji Bio-Pharma,” said Nobu Shimba, President and CEO of Aji Bio-Pharma, US. “With his extensive management experience, we are confident that Tony will be a strong leader for our teams as we provide our clients’ unique drug programs with dedicated attention, strong regulatory support, and focused quality. As we continue to expand our capacity and service offerings, including the addition of our new multi-purpose fill/finish suite, Tony’s expertise will be integral in ensuring the required sterility and regulatory standards are met for both cGMP clinical and commercial manufacturing.”

味の素バイオファーマサービスについて
味の素バイオファーマサービスは、ベルギー、米国、日本、インドに拠点を置く完全統合型の受託開発・製造機関(CDMO)であり、低分子および高分子の原薬(API)および中間体に対し、包括的な開発、cGMPに準拠した製造、無菌充填・仕上げサービスを提供しています。 味の素バイオファーマ・サービスは、Corynex®タンパク質発現技術、オリゴヌクレオチド合成、抗体薬物複合体(ADC)、高活性原薬(HPAPI)、生体触媒、連続フロー製造など、前臨床およびパイロットプログラムから商業生産規模に至るまで、幅広い革新的なプラットフォームと能力を提供しています。 味の素バイオファーマ・サービスは、お客様のニーズに応えるため、高水準の品質とサービスの提供に尽力しています。詳細はこちら:www.AjiBio-Pharma.com

プレスリリース